363 related articles for article (PubMed ID: 30032853)
41. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
Gao G; Ren S; Li A; Xu J; Xu Q; Su C; Guo J; Deng Q; Zhou C
Int J Cancer; 2012 Sep; 131(5):E822-9. PubMed ID: 22161771
[TBL] [Abstract][Full Text] [Related]
42. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Suh CH; Park HS; Kim KW; Pyo J; Hatabu H; Nishino M
Lung Cancer; 2018 Sep; 123():60-69. PubMed ID: 30089596
[TBL] [Abstract][Full Text] [Related]
43. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.
Sekine A; Satoh H
Med Oncol; 2017 Jul; 34(7):121. PubMed ID: 28555261
[TBL] [Abstract][Full Text] [Related]
44. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
45. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
46. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
[TBL] [Abstract][Full Text] [Related]
47. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.
Yoshida H; Kim YH; Iwatsubo S; Sakaguchi C; Sakamori Y; Nagai H; Ozasa H; Mio T; Hirai T
Oncology; 2020; 98(7):460-467. PubMed ID: 32222702
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
49. A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC.
Tan L; Wu Y; Ma X; Yan Y; Shao S; Liu J; Ma H; Liu R; Chai L; Ren J
Pathol Oncol Res; 2019 Apr; 25(2):791-799. PubMed ID: 30761450
[TBL] [Abstract][Full Text] [Related]
50. Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study.
Qian J; He Z; Wu Y; Li H; Zhang Q; Li X
BMC Cancer; 2024 Jan; 24(1):117. PubMed ID: 38262977
[TBL] [Abstract][Full Text] [Related]
51. Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
Shah PP; Franke JL; Medikonda R; Jackson CM; Srivastava S; Choi J; Forde PM; Brahmer JR; Ettinger DS; Feliciano JL; Levy BP; Marrone KA; Naidoo J; Redmond KJ; Kleinberg LR; Lim M
J Neurosurg; 2022 Jan; 136(1):56-66. PubMed ID: 34087798
[TBL] [Abstract][Full Text] [Related]
52. Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Luo S; Chen L; Chen X; Xie X
Oncotarget; 2015 Jun; 6(18):16725-34. PubMed ID: 26057469
[TBL] [Abstract][Full Text] [Related]
53. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
Zeng YD; Zhang L; Liao H; Liang Y; Xu F; Liu JL; Dinglin XX; Chen LK
Asian Pac J Cancer Prev; 2012; 13(3):909-14. PubMed ID: 22631670
[TBL] [Abstract][Full Text] [Related]
54. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
[TBL] [Abstract][Full Text] [Related]
56. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
[TBL] [Abstract][Full Text] [Related]
57. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
[TBL] [Abstract][Full Text] [Related]
58. Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.
Du XJ; Pan SM; Lai SZ; Xu XN; Deng ML; Wang XH; Yao DC; Wu SX
Front Oncol; 2018; 8():603. PubMed ID: 30619745
[No Abstract] [Full Text] [Related]
59. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
60. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.
Singh R; Lehrer EJ; Ko S; Peterson J; Lou Y; Porter AB; Kotecha R; Brown PD; Zaorsky NG; Trifiletti DM
Radiother Oncol; 2020 Mar; 144():165-179. PubMed ID: 31812932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
